{"entity":{"id":"nct07407517","kind":"trial","name":"Adjuvant Intensification for LAR","aka":["POLARIS"],"tldr":"A phase 3 trial in triple-negative breast cancer, run by Fudan University, not yet recruiting.","summary":"Adjuvant Intensification for LAR is a phase 3, randomised interventional study registered as NCT07407517 by Fudan University, with a registry enrolment figure of 904 participants, started 2026-02-01 and due to reach its primary completion in 2033-02-01. Interventions recorded: Everolimus 10 mg daily. Conditions listed: Breast Cancer Females; Triple Negative Breast Cancer (TNBC). Triple-negative eligibility wording from the registry: \"Histologically confirmed invasive triple-negative breast cancer (\\*\\*definition\\*\\*: breast cancer with estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) all confirmed negative by pathology\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07407517","url":"https://clinicaltrials.gov/study/NCT07407517"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07407517","phase":"3","setting":"Standard Chemotherapy Plus Oral Everolimus as Adjuvant Therapy for LAR Breast Cancer Patients: A Randomized, Open-Label, Phase III Trial （POLARIS）","sponsor":"Fudan University","enrolled":904,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07407517/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}